Medtronic (MDT) Falls More Steeply Than Broader Market: What Investors Need to Know

Medtronic (MDT) recently saw its stock decline by 1.4%, underperforming the broader market, despite previous gains that outpaced its sector. Investors are anticipating the company's earnings report on November 18, 2025, where analysts expect Q4 EPS of $1.31 (+3.97% YoY) on $8.84 billion in revenue (+5.26% YoY), with positive full-year growth projected. The medical device firm currently holds a Zacks Rank of #3 (Hold) and trades at a Forward P/E of 17.43, a discount to its industry average, though its PEG ratio of 2.58 is slightly above the industry's 2.27.

Analysis

Medtronic (MDT) experienced a recent daily decline of 1.4% to $96.50, underperforming the broader market indices including the S&P 500's 0.28% loss. This short-term dip contrasts with its prior month's performance, where MDT shares gained 6.01%, surpassing both the Medical sector's 3.31% and the S&P 500's 4.03% gains. The stock's current Zacks Rank is #3 (Hold), reflecting a neutral near-term outlook.

Investors are keenly awaiting Medtronic's earnings report on November 18, 2025, with analysts projecting Q4 EPS of $1.31, representing a 3.97% year-over-year growth. Revenue is anticipated to reach $8.84 billion, a 5.26% increase from the prior year. For the full fiscal year, consensus estimates forecast EPS of $5.62 (+2.37% YoY) and revenue of $35.83 billion (+6.82% YoY), indicating modest growth expectations.

Medtronic's valuation metrics present a mixed picture; its Forward P/E of 17.43 trades at a discount to the industry average of 18.08. However, its PEG ratio of 2.58 is slightly above the industry's 2.27, suggesting a less favorable growth-adjusted valuation. The Medical - Products industry, to which MDT belongs, holds a strong Zacks Industry Rank of 64, placing it in the top 26% of all industries and historically outperforming lower-ranked sectors.

Key Decisions for Investors

• Monitor the upcoming November 18, 2025 earnings report closely for actual results against analyst expectations, particularly revenue growth and any forward guidance.
• Evaluate Medtronic's valuation relative to its industry peers, considering the discount in Forward P/E but the slightly higher PEG ratio, which may signal less compelling growth prospects relative to its price.
• Consider the broader strength of the Medical - Products industry, which could provide a tailwind for MDT, but acknowledge the stagnant Zacks Consensus EPS estimate over the past month.